Resurrect Bio Secures $10.3M to Revolutionize Crop Disease Resistance with AI Gene-Editing
May 19, 2026, 9:38 pm
Resurrect Bio announced a successful $10.3 million Series A funding close. This oversubscribed round powers its cutting-edge gene-editing technology. The UK-based biotech company targets pervasive crop diseases. It reactivates plants' inherent defense mechanisms. Its FloraFold AI platform precisely identifies pathogen weaknesses. The firm then engineers genetic solutions. This approach delivers durable resistance. It significantly lessens the need for harmful chemical inputs. Agricultural giant Corteva led the investment. The new capital will scale Resurrect Bio’s discovery platforms. It will expand strategic collaborations with major seed companies. This accelerates the deployment of resilient crops globally. The initiative marks a pivotal step toward sustainable, high-yield farming. It addresses critical food security challenges worldwide.
Resurrect Bio just closed a $10.3 million Series A funding round. This oversubscribed investment signals strong confidence. The UK-based biotechnology firm is transforming agriculture. It develops advanced gene-editing solutions. These solutions equip crops with robust disease resistance. The capital fuels rapid expansion.
Crop disease presents a persistent global threat. Pathogens devastate harvests. Farmers rely heavily on chemical inputs. This impacts the environment. It raises production costs. Traditional breeding methods are slow. They often lack durable resistance. A new paradigm is essential.
Resurrect Bio offers a groundbreaking approach. The company “resurrects” plants’ innate immunity. Centuries of cultivation weakened these natural defenses. Pathogens evolved. They bypassed plant immune systems. Resurrect Bio reverses this trend.
The core technology centers on plant immune receptors. These are called NLR proteins. Pathogens secrete effector proteins. These effectors bind with NLR proteins. They suppress the plant’s immune response. Resurrect Bio identifies these critical interactions.
Its proprietary FloraFold AI platform is key. FloraFold AI predicts protein-protein interactions. It analyzes crop-pathogen dynamics. This powerful artificial intelligence accelerates discovery. It pinpoints precise vulnerabilities. The platform screens thousands of potential molecular interactions quickly.
The company employs a high-throughput functional biology platform. This validates FloraFold AI predictions. It involves both in-silico (computer simulated) and in-planta (living plant) screening. This ensures accuracy and efficiency.
Once an interaction is identified, Resurrect Bio provides a solution. It determines how to break the pathogen-plant binding. Often, a minute genetic change suffices. A single amino acid alteration can render a plant resistant. This is a powerful, targeted intervention.
Resurrect Bio does not perform the gene editing itself. It partners with seed companies. The company delivers detailed genetic blueprints. These templates guide partners. They implement edits using their own tools. CRISPR technology is one such tool. This model accelerates trait deployment. It leverages existing industry infrastructure.
The benefits are substantial. Plants gain durable, native resistance. This reduces dependence on chemical fungicides. It lessens environmental impact. Crop yields stabilize. Food security improves. The approach applies across diverse crops. It targets multiple pathogens.
Corteva Agriscience led the Series A round. Corteva invested through its Corteva Catalyst platform. This strategic backing validates Resurrect Bio’s potential. Other investors included Calculus Capital, Pymwymic, Future Planet Capital, SynBioVen, and AgFunder. Total capital raised now exceeds $12.4 million.
The new funds will scale Resurrect Bio's platforms. The FloraFold AI system will see further development. Its high-throughput screening capabilities will expand. Team growth is also a priority. More talent will drive innovation forward.
A joint development agreement already exists with Corteva. This partnership focuses on corn disease resistance. Resurrect Bio actively seeks more such agreements. It aims to collaborate with global seed companies. These partnerships will integrate durable resistance traits into commercial pipelines. This is faster than conventional breeding.
Resurrect Bio originated from The Sainsbury Laboratory in the UK. This prestigious research institution provided the foundational science. Founders Sophien Kamoun, Tolga Bozkurt, and Cian Duggan spun out the company in late 2021. Their vision propels agricultural innovation.
The agtech investment landscape is evolving. Corporate venture capital (CVC) plays a critical role. CVC provides patient capital. It offers strategic alignment. This can de-risk early-stage investments for institutional players. Resurrect Bio's success highlights this trend.
The company's technology is foundational. It can address a wide range of agricultural threats. Fungal diseases, oomycetes, and nematodes are all targets. This broad applicability sets Resurrect Bio apart. It promises widespread impact.
Developing resilient crops is paramount. Climate change increases pathogen pressure. Consumer demand for sustainable food grows. Resurrect Bio’s work addresses these urgent challenges. It offers a cleaner, more efficient path to crop protection.
The future of agriculture demands innovation. Gene-editing tools are powerful. They unlock new possibilities. Resurrect Bio stands at the forefront. It combines artificial intelligence with deep plant science. This creates a scalable solution. The company drives progress towards a more secure food supply. Its focus on natural defenses offers long-term sustainability. This investment marks a significant milestone. It accelerates a paradigm shift in crop disease management worldwide.
Resurrect Bio just closed a $10.3 million Series A funding round. This oversubscribed investment signals strong confidence. The UK-based biotechnology firm is transforming agriculture. It develops advanced gene-editing solutions. These solutions equip crops with robust disease resistance. The capital fuels rapid expansion.
Crop disease presents a persistent global threat. Pathogens devastate harvests. Farmers rely heavily on chemical inputs. This impacts the environment. It raises production costs. Traditional breeding methods are slow. They often lack durable resistance. A new paradigm is essential.
Resurrect Bio offers a groundbreaking approach. The company “resurrects” plants’ innate immunity. Centuries of cultivation weakened these natural defenses. Pathogens evolved. They bypassed plant immune systems. Resurrect Bio reverses this trend.
The core technology centers on plant immune receptors. These are called NLR proteins. Pathogens secrete effector proteins. These effectors bind with NLR proteins. They suppress the plant’s immune response. Resurrect Bio identifies these critical interactions.
Its proprietary FloraFold AI platform is key. FloraFold AI predicts protein-protein interactions. It analyzes crop-pathogen dynamics. This powerful artificial intelligence accelerates discovery. It pinpoints precise vulnerabilities. The platform screens thousands of potential molecular interactions quickly.
The company employs a high-throughput functional biology platform. This validates FloraFold AI predictions. It involves both in-silico (computer simulated) and in-planta (living plant) screening. This ensures accuracy and efficiency.
Once an interaction is identified, Resurrect Bio provides a solution. It determines how to break the pathogen-plant binding. Often, a minute genetic change suffices. A single amino acid alteration can render a plant resistant. This is a powerful, targeted intervention.
Resurrect Bio does not perform the gene editing itself. It partners with seed companies. The company delivers detailed genetic blueprints. These templates guide partners. They implement edits using their own tools. CRISPR technology is one such tool. This model accelerates trait deployment. It leverages existing industry infrastructure.
The benefits are substantial. Plants gain durable, native resistance. This reduces dependence on chemical fungicides. It lessens environmental impact. Crop yields stabilize. Food security improves. The approach applies across diverse crops. It targets multiple pathogens.
Corteva Agriscience led the Series A round. Corteva invested through its Corteva Catalyst platform. This strategic backing validates Resurrect Bio’s potential. Other investors included Calculus Capital, Pymwymic, Future Planet Capital, SynBioVen, and AgFunder. Total capital raised now exceeds $12.4 million.
The new funds will scale Resurrect Bio's platforms. The FloraFold AI system will see further development. Its high-throughput screening capabilities will expand. Team growth is also a priority. More talent will drive innovation forward.
A joint development agreement already exists with Corteva. This partnership focuses on corn disease resistance. Resurrect Bio actively seeks more such agreements. It aims to collaborate with global seed companies. These partnerships will integrate durable resistance traits into commercial pipelines. This is faster than conventional breeding.
Resurrect Bio originated from The Sainsbury Laboratory in the UK. This prestigious research institution provided the foundational science. Founders Sophien Kamoun, Tolga Bozkurt, and Cian Duggan spun out the company in late 2021. Their vision propels agricultural innovation.
The agtech investment landscape is evolving. Corporate venture capital (CVC) plays a critical role. CVC provides patient capital. It offers strategic alignment. This can de-risk early-stage investments for institutional players. Resurrect Bio's success highlights this trend.
The company's technology is foundational. It can address a wide range of agricultural threats. Fungal diseases, oomycetes, and nematodes are all targets. This broad applicability sets Resurrect Bio apart. It promises widespread impact.
Developing resilient crops is paramount. Climate change increases pathogen pressure. Consumer demand for sustainable food grows. Resurrect Bio’s work addresses these urgent challenges. It offers a cleaner, more efficient path to crop protection.
The future of agriculture demands innovation. Gene-editing tools are powerful. They unlock new possibilities. Resurrect Bio stands at the forefront. It combines artificial intelligence with deep plant science. This creates a scalable solution. The company drives progress towards a more secure food supply. Its focus on natural defenses offers long-term sustainability. This investment marks a significant milestone. It accelerates a paradigm shift in crop disease management worldwide.